Skip to contentSkip to content

The Hatch Report

Features, explainers, and a curious look at the news
ExplainersCultureBooksScience & NatureCommentaryVideoProfilesBusinessFinance Search
RushDATA™ Enables Wet-Lab Validation of AI-Designed Antibodies Generated by Molence Bio's Mol-1
Business

RushDATA™ Enables Wet-Lab Validation of AI-Designed Antibodies Generated by Molence Bio’s Mol-1

CAMBRIDGE, Mass., Nov. 13, 2026 /PRNewswire/ -- Biointron Biological USA Inc. ("Biointron") is pleased to have supported Molence Bio's Mol-1 project. Mol-1 demonstrates performance comparable to the leading closed-source model IsoDDE in antibody-antigen structure prediction and is capable…

The Hatch Report Press Desk

November 17, 2026 at 3:07 pm · 2 min read

RushDATA™ Enables Wet-Lab Validation of AI-Designed Antibodies Generated by Molence Bio's Mol-1

Tech

BiointronNovember 17, 2026

CAMBRIDGE, Mass., Nov. 13, 2026 /PRNewswire/ — Biointron Biological USA Inc. (“Biointron”) is pleased to have supported Molence Bio’s Mol-1 project. Mol-1 demonstrates performance comparable to the leading closed-source model IsoDDE in antibody-antigen structure prediction and is capable of designing functional nanobodies from scratch. To experimentally evaluate these AI-designed candidates, Biointron conducted developability assays using RushDATA™, its wet-lab validation service for AI-designed antibodies.

Biointron's RushDATA™ Enables Wet-Lab Validation of AI-Designed Antibodies Generated by Molence Bio’s Mol-1

The results: 23 out of 30 AI-designed candidates met at least three of the four developability criteria, demonstrating promising developability profiles.

Wet-Lab Validation with RushDATA™

AI-designed antibodies require experimental validation to demonstrate their potential as viable drug candidates. Biointron ran the developability panel on Molence Bio’s VHH-Fc candidates, measuring properties that predict manufacturability and safety, including hydrophobicity, thermal stability, self-interaction, and non-specific binding.

Each assay was benchmarked against Biointron reference antibodies, including infliximab, bevacizumab, bococizumab, gantenerumab and trastuzumab, so the designs could be compared directly with approved and clinical-stage antibodies.

Bridging AI Design and Wet-Lab Validation

RushDATA™ is Biointron’s wet-lab validation service for AI-designed antibodies, combining a capacity of 10,000+ antibodies per day with sequence-to-data turnaround in as little as 2 days with cell-free expression or 3 days with CHO expression.

The service offers multi-point binding affinity measurements by BLI or SPR, alongside developability profiling using DSF, PSR-BVP, and AC-SINS. Results are delivered as structured, model-ready datasets with API access, allowing experimental findings to feed directly into the next round of AI-guided design.

Why This Matters for AI-Driven Antibody Discovery

AI can now generate antibody binders at scale. The next challenge is proving which designs work in the lab and behave like drugs. Mol-1 shows what happens when a strong open model meets high-quality experimental data, and Biointron is proud to provide that data.

Biointron congratulates Molence Bio on the launch of Mol-1 and looks forward to supporting the researchers who build on it.

About Biointron

Founded in 2012, Biointron is a global antibody discovery CRO trusted by 3,000+ organizations in 20+ countries and regions, including top 20 pharma companies. Our RushDATA™ platform generates wet-lab data for AI-designed antibodies at scale, expressing 10,000+ antibodies a day and delivering binding and developability results in as little as 2 days, ready to feed your models via API. We also offer end-to-end antibody services from discovery to large-scale production. Several partner projects using our CHOK1BN cell line have entered multicenter international clinical trials successfully.

Learn more about RushDATA™: https://www.biointron.com/antibody-production/rushdata.html

About Molence Bio

Molence Bio is an AI-native biotech built on their own biomolecular foundation models. Their biologists, chemists, and AI researchers work side by side to advance these models and apply them to drug discovery: unlocking targets long considered undruggable, designing better molecules, and building a pipeline of therapies for unmet medical needs.

Access the model weights: https://github.com/molence/Mol-1

Contact

Media contact: Mia Deng

Biointron

+1 (732) 790-8340

info@biointron.com

20 University Road, Suite 500, Cambridge, MA 02138 

Founded in 2012, Biointron is a CRO specializing in antibody discovery, expression, and optimization services for biotech and pharmaceutical companies. From gene sequence to purified antibodies, our production takes only 2 weeks — and with RushData, our AI antibody wet lab validation service, computational predictions become experimentally confirmed candidates at high throughput.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/rushdata-enables-wet-lab-validation-of-ai-designed-antibodies-generated-by-molence-bios-mol-1-302942789.html

SOURCE Biointron

Distributed by PR Newswire / Cision.

More Business

The Asus Eee PC 2G Surf and the Rise and Fall of the Netbook

The Asus Eee PC 2G Surf and the Rise and Fall of the Netbook

Business School for an Entrepreneur: MBA vs. Part-Time MBA vs. EMBA

Business School for an Entrepreneur: MBA vs. Part-Time MBA vs. EMBA

The Evolution of Property, From Land to Ideas

The Evolution of Property, From Land to Ideas

The Briefing

  1. 01The 401(k) limit is $24,500 this year. Next year it will be $25,500
  2. 02Camels Don’t Store Water in Their Humps
  3. 03If you want your Social Security COLA letter online, the deadline is Nov. 18
  4. 04Dispelling Myths About Camels
  5. 05Medicare’s Part B premium is $202.90 this year. The 2027 rate is not out yet
  6. 06The Asus Eee PC 2G Surf and the Rise and Fall of the Netbook

Sections

  • Explainers
  • Culture
  • Books
  • Science & Nature
  • Commentary
  • Video
  • Profiles
  • Business
  • Finance

The Hatch Report

Features, explainers, and a curious look at the news

AboutMastheadContactEditorial PolicyPrivacyTerms

© 2026 The Hatch Report